Tin tức & Cập nhật

In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).

One in five patients with neovascular age-related macular degeneration (nAMD) fail to start treatment within 1 year of presentation, reports a study. Factors associated with lower treatment initiation include Asian race, age <60 years, and low-vision status, among others.

Two phase III induction trials have demonstrated the efficacy and safety of obefazimod, an oral, first-in-class, small molecule, for the treatment of adults with moderate-to-severe ulcerative colitis (UC).